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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYHuman embryonic stem cells (hESCs) regularly acquire nonrandom genomic aberrations during culture, raising concerns about their safe
therapeutic application. The International Stem Cell Initiative identified a copy number variant (CNV) amplification of chromosome
20q11.21 in 25% of hESC lines displaying a normal karyotype. By comparing four cell lines paired for the presence or absence of
this CNV, we show that those containing this amplicon have higher population doubling rates, attributable to enhanced cell survival
through resistance to apoptosis. Of the three genes encoded within the minimal amplicon and expressed in hESCs, only overexpression
of BCL2L1 (BCL-XL isoform) provides control cells with growth characteristics similar to those of CNV-containing cells, whereas inhibi-
tion of BCL-XL suppresses the growth advantage of CNV cells, establishing BCL2L1 as a driver mutation. Amplification of the 20q11.21
region is also detectable in human embryonal carcinoma cell lines and some teratocarcinomas, linking this mutation with malignant
transformation.INTRODUCTION
Human embryonic stem cells (hESCs) have an indefinite
capacity to self-renew, a key attribute that is necessary for
the scale-up production required to translate their poten-
tial into direct clinical and industrial applications. How-
ever, during progressive culture, cells are susceptible to
acquiring genetic and chromosomal abnormalities, which
can provide a competitive growth advantage and become
fixed in the population. Chromosomal aberrations in
hESCs are nonrandom and commonly involve gains of
chromosomes (or fragments of) 1, 12, 17, and X (Amps
et al., 2011; Baker et al., 2007; Cowan et al., 2004; Draper
et al., 2004; Inzunza et al., 2004), which are also commonly
observed in human embryonal carcinoma cells (hECCs),
the stem cells of teratocarcinomas (Reuter, 2005; Summers-
gill et al., 2001). Although this selection clearly reflects
culture adaptation to an in vitro environment due to
increases in the cell growth rate, survival, or suppression
of differentiation, the region selected may also comprise
or formpart of stem cell neoplastic progression. Identifying
possible driver mutations for this process is a majorStem Cell Rchallenge, due in part to the relatively large genomic size
of the chromosomal amplifications and the number of
genes encompassed. The pluripotency gene NANOG,
which maps to chromosome 12 (p13.31), is a potential
candidate for driving the establishment of chromosome
12 duplication; however, it is not uniformly present in
the minimal amplicons identified in hECCs. Recently,
molecular karyotyping by SNP array and array comparative
genomic hybridization (aCGH) analysis has revealed
another amplification that is common among hESC lines,
representing chromosome 20q11.21 (Amps et al., 2011;
Elliott et al., 2010; Laurent et al., 2011; Lefort et al., 2008;
Na¨rva¨ et al., 2010; Spits et al., 2008; Werbowetski-Ogilvie
et al., 2009). This copy number variant (CNV) was present
in >20% of 125 screened hESC lines, with aminimal ampli-
con of 0.55 MB (Amps et al., 2011), and in 18% of 34
screened human induced pluripotent cells (hiPSCs) (Mar-
tins-Taylor et al., 2011). The amplification is not of donor
origin, but arises during culture. In this study, we aimed
to determine whether this amplification confers a competi-
tive advantage to the cells, define the mechanism behind
the advantage, and identify the driving mutation.eports j Vol. 1 j 379–386 j November 19, 2013 j ª2013 The Authors 379
29,845,467 30,073,581 30,326,904 30,639,991 30,946,147 31,290,493
DEFB115
DEFB116
DEFB118
DEFB119
TTLL9
FOXS1
MYLK2
COX4I2
ID1
HM13
LINC00028
DEFB124
DEFB123
DEFB122
DEFB121
miR-3193
psiMCT-1
BCL2L1
TPX2
DUSP15
C20orf112
ASXL1
KIF3B
C20orf160
POFUT1
PLAGL2
HCK
XKR7
PDRG1
TM9SF4
C20orf203
COMMD7
DNMT3B
MAPRE1
SUN5
HES3
ESI035
H1
Shef5
REM1
29,641,495 31,347,910
*
B
A
Shef5 
0.0
0.5
1.0
1.5
2.0
2.5
ESI035
0.0
0.5
1.0
1.5
2.0
2.5
H1 
0.0
0.5
1.0
1.5
2.0
2.5
HES3 
DE
FB
11
5
RE
M1
TP
X2
MY
LK
2
XK
R7
TM
9S
F4
AS
XL
1
DN
MT
3B
BP
IFB
1
RA
LY
RE
LL
1
RP
PH
1
EP
HA
5
0.0
0.5
1.0
1.5
2.0
2.5
Chromosome 20q11.21
29
,84
6,5
27
30
,06
5,8
98
30
,32
8,0
58
30
,41
0,4
28
30
,57
2,5
01
30
,70
2,0
72
30
,95
1,6
92
31
,36
7,2
56
31
,87
2,1
83
32
,61
0,6
31
(C
h4
) 3
7,6
63
,78
6
 (C
h1
4) 
20
,81
1,3
18
(C
h4
) 6
6,5
33
,33
9 Figure 1. Presence of 20q11.21 Gain in
Four Test hESC Lines
(A) Genomic qPCR assay using primer/probe
pairs designed to introns of genes spanning
the 20q11.21 locus (black bars) determines
the amplicon length and copy number fold
change. Genomic positions relate to USCS
human genome assembly version hg19
(Kent et al., 2002). Cycle threshold values
are normalized against RELL1 (first white
bar) genomic values. RELL1 is located on
chromosome 4, which displays a low inci-
dence of genomic instability in hESCs. Two
additional controls (white bars) confirm the
suitability of the first control. All data are
normalized against control hESCs.
(B) Schematic representation of amplicon
lengths for the four test hESC cell lines (red
lines) positioned alongside genes con-
tained within the 20q11.21 locus. The green
dotted line and asterisk represent the
minimal amplicon previously described in
hESCs, and genes in blue are candidate
genes located within the minimal amplicon
and expressed in hESCs.
See also Figure S1 and Table S4.
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BCL-XL Drives Selection of 20q11.21 CNV in hESCsRESULTS AND DISCUSSION
We studied four independent hESC lines: HES3, H1, ESI-
035, and Shef5. Cultures from these four cell lines that
had been reported to contain a 20q11.21 CNV were paired
with cultures from previous passages that did not appear to
be positive for the CNV by SNP array (Amps et al., 2011).380 Stem Cell Reports j Vol. 1 j 379–386 j November 19, 2013 j ª2013 TheHereafter, we refer to these lines as CNV and control lines,
respectively. Upon receipt of these cell lines, we confirmed
the presence and length of the CNV by quantitative PCR
(qPCR; Figures 1A and 1B). HES3-CNV contained the
longest CNV, followed by H1-CNV, ESI-035-CNV, and
Shef5-CNV in descending order. Reference banks of these
cells were prepared and karyotype analysis was performed.Authors
Stem Cell Reports
BCL-XL Drives Selection of 20q11.21 CNV in hESCsEach cell had a normal karyotype when it was received,
with the exception of Shef5-CNV, in which one of the X
chromosomes was absent (Table S1 available online).
Fluorescence in situ hybridization (FISH) analysis for the
BCL2L1 locus indicated the presence of the amplicon in
all CNV lines and multiple extra copies in HES3 and H1
CNV cells. However, the control HES3 and H1 lines that
we received also displayed a degree of mosaicism for the
CNV, most likely reflecting the propensity of cells to
acquire this CNV and gain a selective advantage (Amps
et al., 2011). Nevertheless, as a population, the dosage
was much lower than that of CNV cells (average
20q11.21 copies: HES3 control 2.2, HES3-CNV 3.5, H1
control 2.5, and H1-CNV 4.2), enabling culture compari-
sons (Table S1). All of the cell lines formed teratomas
when injected into immunocompromised mice, with no
apparent differences in differentiation potential.
ESI-035 and HES3 control cells were transfected with
HM13, ID1, or BCL-XL expression constructs to generate
individual, constitutively overexpressing sublines reflect-
ing the three hESC-expressed genes located within the
minimal CNV. The gene BCL2L1 encodes two splice vari-
ants: the antiapoptotic BCL-XL and the proapoptotic
BCL-XS. Since RNA sequencing data show that BCL-XL is
the dominant isoform expressed in hESCs and the only iso-
form in which protein was detected (Figures S1A and S1B),
BCL-XS-overexpressing cells were not generated. BCL-XL
serves to relocate the proapoptotic protein BAX away
from mitochondria and back to the cytosol, thereby pre-
venting cellular apoptosis (Edlich et al., 2011). In addition,
BCL-XL also promotes cell survival by binding to and
inhibiting Beclin-1 to inhibit stress-induced autophagy
(Maiuri et al., 2007). HM13 is a minor histocompatibility
antigen that influences anchorage-independent growth
of SW480 cells (Sillars-Hardebol et al., 2012b), whereas
the basic-helix-loop protein ID1 has a role in maintaining
the self-renewal of mouse ESCs (Ying et al., 2003) and pro-
motes tumor metastasis (Gumireddy et al., 2009).
To determine whether the 20q11.21 CNV provides a
selective advantage, we compared growth rates for the
paired cell lines by counting the total number of cells
4 days after seeding at a density of 8 3 104 cells/cm2 (Fig-
ure 2A), a density that reflects the typical seed density dur-
ing routine cell passage. In all cases, CNV cells displayed a
higher population growth rate than control cells, with a
collective average of three times as many cells. In addition,
CNV cells appeared to be less dependent upon the initial
seed density, with average cell counts 5-fold and 7-fold
greater than control cells following seeding at the lower
densities of 43 104 cells/cm2 and 23 104 cells/cm2, respec-
tively (Figure S2). This increased growth rate was also
mimicked by ESI-035 cells overexpressing BCL-XL, but
not by those overexpressing either HM13 or ID1. To furtherStem Cell Rassess the kinetics of the growth advantage in mixed cul-
tures, we performed competition assays using HES3 cells.
For this purpose, we mixed GFP-expressing HES3 control
cells at a ratio of 9:1 with HES3 control, CNV, or HES3 over-
expressing each of the three candidate genes (Figure 2B).
The HES3-CNV and HES3-BCL-XL-overexpressing cells
rapidly outcompeted the GFP-expressing control cells,
with the 9:1 ratio reversed to 1:9 by passage 10, whereas
the ratio of green/nongreen cells was maintained in cul-
tures containing control, HES3-HM13, and HES3-ID1 cells.
This again highlights the similar characteristics of CNV
and BCL-XL-overexpressing cells and demonstrates how
rapidly these cells are selected for in mixed cultures. By
contrast, small-molecule inhibition of BCL-XL with the
compound ABT-263 reduced the high cloning efficiency
of CNV cells to levels comparable to those observed in
the untreated control cells at a concentration of 250 nM
(Figure 2C). In addition, when BCL-XL protein levels
were reduced inH1CNV cells (by induced shRNAi) to levels
comparable to those in control cells, we observed a strong
reduction in the growth rate of these cells (Figures 2D
and S2B). These data further support the notion that
BCL-XL confers the growth advantage observed in CNV
cells. We also confirmed that CNV cells, which have
increased copies of BCL2L1, had higher levels of BCL-XL
protein than the control cells, as would be expected if
BCL-XL were responsible for the selective advantage
(Figure S1B).
We next determined whether the observed growth
advantage for cells containing the 20q11.2 CNV resulted
from increased cell-cycle rates or enhanced cell survival.
A comparison of cell-cycle distribution revealed very little
difference between CNV and control cells, or cells overex-
pressing HM13 or ID1 (Figure 3A). One might expect cells
that cycle more quickly to display higher proportions of
cells in S phase, a feature that was previously observed in
culture-adapted hESCs (Yang et al., 2008). The CNV cells,
however, had slightly fewer cells in S phase and more in
G0/1 than the control cells, and this difference was most
notable between the HES3 and H1 pairs. The difference
was most exemplified by ESI-035-BCL-XL cells, which dis-
played a far smaller proportion of cells in S phase compared
with the other ESI-035 subtypes, and a greater proportion
of cells in G0/1. It was previously reported that BCL-XL
plays a role in the cell cycle, such that overexpression of
BCL-XL delays the cellular G0/1-to-S phase transition
(Greider et al., 2002; O’Reilly et al., 1996). Although it
was suggested that this delay is primarily a result of G0 pro-
longation rather than a prolonged G1 phase (Janumyan
et al., 2003), the observations made here in hESCs would
more likely indicate a prolonged G1 phase, since actively
cycling hESCs do not enter a quiescent GO phase (Becker
et al., 2006).eports j Vol. 1 j 379–386 j November 19, 2013 j ª2013 The Authors 381
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Figure 2. CNV and BCL-XL-Overexpress-
ing hESCs Display Enhanced Growth Rates
(A) Cell densities for hESCs lines: control
(blue circle), CNV-containing (red circle), or
overexpressing HM13 (orange circle), ID1
(purple circle), or BCL-XL (black circle).
Cells were seeded at 8 3 104 cells/cm2 and
cultured for 96 hr before total cell counts
were obtained. Error bars: SEM from three
independent experiments. Asterisks indi-
cate statistical significance by two-tailed
t test; *p % 0.05, **p % 0.01, ***p %
0.001.
(B) Cell competition assay between HES3
cells. HES3-GFP-expressing control cells
were mixed at a 9:1 ratio with control cells,
CNV cells, or HES cells overexpressing HM13,
ID1, or BCL-XL. The GFP percentage was
measured by flow cytometry over the course
of ten passages (P). Error bars: SEM from
three independent experiments.
(C) The clonogenicity of CNV cells is reduced
to normal levels by inhibition of BCL-XL
using the compound ABT-263. Control cells
(green wells) and CNV cells (red wells) were
seeded at 13 104 cells/cm2 and cultured for
5–7 days. CNV cells were untreated (i) or
treated with ABT-263 at 50 nM (ii), 100 nM
(iii), 250 nM (iv), or 1,000 nM (v) concen-
trations.
(D) Cell densities obtained for H1 CNV BCL-
XL-shRNAi cells seeded at 83 104 cells/cm2
treated in the presence of 100 ng/ml
doxycycline (Dox+), or not (Dox-), for 96 hr.
Cells were seeded at 8 3 104 cells/cm2 and
cultured for 96 hr before total cell counts
were obtained. Error bars: SEM from three
independent experiments. Asterisks indi-
cate statistical significance by two-tailed
t test (p < 0.005).
See also Figure S2.
Stem Cell Reports
BCL-XL Drives Selection of 20q11.21 CNV in hESCsTime-lapse microscopy was used to measure the actual
time between cell divisions (Figure 3B). We observed that
the cycle times were quite variable, ranging from as short
as 7 hr to longer than 44 hr. The average times per cell divi-
sion, however, were almost identical and, with exception
of the H1 cell line, were not statistically significantly
different between paired CNV and control cell lines. The
difference in average cell-cycle time between H1 pairs is ex-
plained by a much tighter clustering of division times for
the CNV cells compared with the control cells, whose
average division times were increased by a number of
much slower cell divisions. We observed some slight inter-
cell variations between the cell lines, with Shef5 cells
having extended cell-cycle times compared with the other382 Stem Cell Reports j Vol. 1 j 379–386 j November 19, 2013 j ª2013 Thecell lines. HM13- and BCL-XL-overexpressing cells had
slightly increased cycle times compared with control cells,
but it is unclear whether this represents true differences
between the cells, which have a wide distribution of cycle
times.
The actual cell division times, averaging 19.5 and 18.5 hr
for control and CNV cells, respectively, were in stark
contrast to the assessed population doubling times, which
after 4 days were measured on average as 138 hr and 35 hr,
respectively. The difference in these values reflects the high
percentage of cell death that occurred within cultures,
particularly among control cells. By mapping cell fates
over the first 24 hr, we found extensive cell death after
plating, which was most apparent in the control cellsAuthors
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Figure 3. Cell Survival, not Cell Cycle,
Influences the Growth Advantage for
CNV and BCL-XL-Overexpressing hESCs
In each panel, cells are labeled as control
(blue circle), CNV-containing (red circle),
overexpressing HM13 (yellow circle), over-
expressing ID1 (purple circle), or overex-
pressing BCL-XL (black circle).
(A) Cell-cycle distribution percentages for
cells in G0/1, S, or G2/M phase. Error bars:
SEM from three independent experiments.
Asterisks indicate statistical significance by
two-tailed t-test; *p% 0.05, **p% 0.01.
(B) Actual cell division times. Each spot
represents the time period between two cell
divisions; mean average and SEM are indi-
cated by black lines. A two-tailed t test
analysis was performed to compare differ-
ences between test and control cells. Actual
p values are provided for test cells with
significant differences (p < 0.05).
(C) Cell-fate maps based upon time-lapse
movie observations over 24 hr for control
cells (blue bars) and CNV cells (red bars),
where fates are measured as living (d) or
dead (y) cells. Percentage outcomes (50
randomly selected cells from ten fields per
group) represent cell death (1), cell division
with both daughter cells dying (2), cell does
not divide but survives (3), cell divisionwith
only one daughter cell surviving (4), and cell
division with both daughter cells surviving
(5). For all four lines, control and CNV cells
exhibited significantly different frequencies
of outcomes 1 and 5 (c2 test, p < 0.05).
(D) Cell-staining percentages for cleaved
caspase-3. Measurements were taken over
the course of 24 hr. Error bars: SEM from
three independent experiments. Asterisks
indicate significant differences between
control and CNV cells by 6 hr (HES3, H1, ESI,
ESI+BCL-XL) or 12 hr (Shef5); two-way
ANOVA, p < 0.05.
See also Figure S3.
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BCL-XL Drives Selection of 20q11.21 CNV in hESCs(Figure 3C). On average, 70% of the control cells had died,
compared with 41% of CNV cells. By contrast, only 7% of
the control cells divided during this period, with both
daughter cells surviving, whereas 30% of the CNV cells suc-
cessfully achieved this outcome. These observations were
supported by the percentage of cells that were positive for
the cleaved form of capsase-3, a measure of early apoptosis
(Figure 3D). The stress placed upon the cells during
passaging resulted in increased proportions of cells under-
going apoptosis. By 24 hr, approximately 60% of control
cells were positive for cleaved caspase-3, compared withStem Cell Ronly about 30% for CNV cells. These values were reversed
in H1 CNV cells when BCL-XL protein levels were reduced
by induced shRNAi, highlighting the protection from
apoptosis conferred by BCL-XL (Figure S3). Our observa-
tions of high death rates following passage underscore
the need to routinely split hESCs at relatively low split
ratios.
hECCs have similarities to hESCs with respect to cellular
properties and acquisition of specific genomic aberrations.
We therefore investigated whether hECCs have also
acquired the 20q11.21 CNV. Amplification of this regioneports j Vol. 1 j 379–386 j November 19, 2013 j ª2013 The Authors 383
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Figure 4. Presence of 20q11.21 Amplicon and Increased BCL-
XL Protein Expression in Several ECC Lines
(A) Representative figures for FISH analysis of the nine ECCs.
Orange probe, BCL2L1 spectrum; green probe, 20 p telomere
spectrum. The number of BCL2L1 copies is indicated at the bottom
right of each panel. Scale bar: 2 mm.
(B) Western blot analysis for BCL-XL and Bcl-xS protein using a
universal BCL-X antibody. Whole-cell lysates were prepared from
hECCs. b-actin was used as a loading control.
See also Figure S4.
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BCL-XL Drives Selection of 20q11.21 CNV in hESCswas detected in six of nine hECC lines studied, as
determined by FISH analysis, and there was a positive cor-
relation between amplification of the BCL2L1 locus and
BCL-XL (but not BCL-XS) protein expression (Figure 4;
Table S2). Further, of 13 clinical samples of primary embry-
onal carcinoma checked by SNP analysis, two displayed
chromosome 20 gains. One showed a high-level focal
amplification in the 20q11.21 region, and the other
showed low-level amplification across the whole of chro-
mosome 20 (Figure S4). The presence of the 20q11.21
amplicon in hECCs further highlights their similarity to
hESCs and suggests that the CNV may represent a feature
of neoplasia. Amplification of the locus, therefore, may
not be simply an adaptation of cells during in vitro culture,
but may represent a driver mutation in a percentage of
human teratocarcinomas (15% in this relatively small
sample).
The gain of 20q11.21 is not specific to pluripotent cells
and is a common feature of many screened cancer cells384 Stem Cell Reports j Vol. 1 j 379–386 j November 19, 2013 j ª2013 Theand cancer types in which knockdown of BCL2L1 is detri-
mental to cancer cell proliferation (Beroukhim et al.,
2010). It has also been suggested that 20q amplification is
strongly correlated with colorectal adenoma-to-carcinoma
progression, and that BCL2L1mayhave a functional role in
this transition (Carvalho et al., 2009; Sillars-Hardebol et al.,
2012a). In addition to a role in metastasis, there is also an
inverse relationship between BCL-XL expression and the
chemosensitivity of cancer cell lines (Amundson et al.,
2000). Indeed, BCL-XL contributes to chemoresistance
and recurrent disease in ovarian carcinoma patients (Wil-
liams et al., 2005). This not only compounds the potential
risk of using hESCs that harbor 20q11.21 CNV in therapy
but may also have negative implications for the use of
such cells in pharmaceutical toxicological assays.
Gain of 20q11.21 provides hESCs with a considerable
growth advantage over their non-CNV counterparts
through protection against apoptosis, and high expression
of BCL-XL is most likely responsible for this growth advan-
tage. Resistance to apoptosis may render cells susceptible to
additional aberrations, since apoptotic mechanisms are
known to eliminate cells acquiring genomic mutations
(Hyka-Nouspikel et al., 2012). It was previously observed
that overexpression of another BCL family member,
BCL2, also confers a selective advantage to hESCs (Ardehali
et al., 2011). In contrast to the case with BCL2L1, however,
the evidence does not suggest that hESCs select for BCL2
copy number gains, despite the presumption that both
genes should confer a similar antiapoptotic selective
advantage. It is the combination of having a mutation
hotspot in the genome in the vicinity of an antiapoptotic
gene (in this instance BCL-XL) that drives such a strong
selection for the 20q11.21 mutation.
Although it is common practice to screen hESCs for
larger-scale genomic mutations by karyotype analysis,
amplicons measuring <5 Mb are not detected by conven-
tional G-band analysis. Thus, relatively small 20q11.21
amplifications encompassing BCL2L1, which alter cell-
growth characteristics, will not be readily detected. Because
of the association of gains of this regionwith neoplasia and
chemoresistance, we stress that regular screening by a
simple genomic qPCR-based approach and/or FISH is vital
to ensure the quality of pluripotent hESC and hIPSC
cultures.EXPERIMENTAL PROCEDURES
hESC Lines and Culture
We used the following hESC cell lines: HES3 (Reubinoff
et al., 2000), ESI-035 (Crook et al., 2007), Shef5 (Aflatoonian
et al., 2010), and H1 (Thomson et al., 1998). Cells were cultured
in mTeSR1 (StemCell Technologies) on plates coated with
Matrigel (BD Biosciences), which was diluted 1:50 in Dulbecco’sAuthors
Stem Cell Reports
BCL-XL Drives Selection of 20q11.21 CNV in hESCsmodified Eagle’s medium (DMEM)/F12 (Invitrogen). Cultures
were incubated at 37C under a humidified atmosphere of 5%
CO2. Stock cultures were split every 5–7 days by manual
dissection.
For details regarding the materials and methods used, see the
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and four tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2013.10.005.
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